Zhenduanxue lilun yu shijian (Aug 2022)
Clinical value of serum pepsinogen,gastrin 17 and Helicobacter pylori IgG antibody in primary screening of gastric diseases
Abstract
Objective: To explore the clinical value of serum PGI, PGII, PGI/PGII, G-17 levels and Hp-IgG antibody in the preliminary screening of gastric diseases. Methods: A total of 300 patients who underwent gastroscopy in the Gastroenterology Department of our hospital from July 2018 to July 2020 due to gastric diseases were selected as the research objects. According to gastroscopy and pathological examinations, they were divided into chronic superficial gastritis group,chronic atrophic gastritis group and gastric cancer group. 100 healthy patients from the physical examination center during the same period were selected as the control group. The serum PGI, PGII, PGI/PGII G17 levels and the positive rate of Hp-IgG antibody in each group were compared. Results: Serum PGI/PGII levels in gastric cancer group(10.42±4.63) and atrophic gastritis group (10.54±4.36) were lower than those in control group (12.07±6.80). Serum G-17 levels in gastric cancer group [(13.85±27.68） pmmol/L] and chronic atrophic gastritis group [(9.63±10.82) pmmol/L] were higher than those in control group [(6.02±7.30) pmmol/L]. The serum PGI level in gastric cancer group[(123.53±35.45) μg/L] was lower than that in the control group[(148.24±83.85) μg/L and chronic superficial gastritis group [(141.95±81.11) μg/L]. The differences were statistically significant (P<0.05). The positive rate of Hp-IgG antibody in gastric cancer group (50.75%) and atrophic gastritis group (50.00%) was higher than that of the control group (35.00%), and the difference was statistically significant (P<0.05). Conclusions: Serum PGI, PGII, PGI/PGII, G-17 levels and Hp-IgG antibody detection can be used for the primary screening of gastric diseases, which can identify high-risk groups of gastric cancer and provide a reliable reference for further screening of gastric cancer.
Keywords
